Company Overview of Transplant Genomics, Inc.
Transplant Genomics, Inc., a molecular diagnostic company, develops molecular diagnostic tests that detect early signs of graft injury, differentiate among actionable causes, and enable optimization of therapy. It focuses on improving organ transplant outcomes. The company was founded in 2013 and is based in Brookline, Massachusetts.
1501 Beacon Street
Brookline, MA 02446
Founded in 2013
Key Executives for Transplant Genomics, Inc.
Chief Executive Officer and President
Compensation as of Fiscal Year 2014.
Transplant Genomics, Inc. Key Developments
Transplant Genomics Appoints Brett R. Jensen as Vice President of Sales
Nov 12 14
Transplant Genomics, Inc. announced the appointment of senior healthcare sales and marketing leader Brett R. Jensen to the position of Vice President, Sales. In his role, Jensen will be responsible for initiating partnerships with kidney transplant centers and overseeing the company's sales strategy as well as leading reimbursement activities. Jensen has more than 25 years of experience in business growth, organizational leadership, and product and market development in molecular diagnostics and pharmaceuticals. Prior to joining TGI, Jensen served as Sales and Marketing Director in Myriad Genetics' urology business unit. He played a key role in reimbursement for Myriad's prostate cancer genomic signature by obtaining a positive Draft Local Coverage Determination by Medicare and by achieving its inclusion in the National Comprehensive Cancer Network prostate cancer guidelines. He also held numerous sales and marketing positions at GlaxoSmithKline in a wide range of disease areas.
Transplant Genomics Announces an Exclusive License to Patent Rights Co-Owned by The Scripps Research Institute and Northwestern University
Jul 14 14
Transplant Genomics announced it has an exclusive license to patent rights co-owned by The Scripps Research Institute and Northwestern University. According to announcement, the company intends to develop and commercialize tests to monitor how well transplants are faring, and to detect and respond to early signs of problems with the graft. It first plans to focus on a test for kidney transplant recipients that can show when treatment or biopsy is required based on analysis of a patient's blood.
Similar Private Companies By Industry
Recent Private Companies Transactions
November 24, 2014
Most Searched Private Companies
Sponsored Financial Commentaries